# Dina Chaya

> Dina Chaya is a Series B investor at OrbiMed (London) backing Biotechnology and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors)
- Location: London, United Kingdom
- Total investments: 7
- Last investment: Dec 2025
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: http://uk.linkedin.com/pub/dina-chaya/13/53a/2
- Facebook: https://www.facebook.com/dina.chaya

Dina Chaya is a Series B investor at OrbiMed in London focused on Biotechnology and Health Care. Dina Chaya is based out of London, England and is the Partner of OrbiMed. Dina previously worked at Omega Funds as a Partner. Dina Chaya attended the Pierre and Marie Curie University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 71% |
| Health Care | 4 | 57% |
| Pharmaceutical | 3 | 43% |
| Therapeutics | 2 | 29% |
| Medical Device | 2 | 29% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Series A | 2 | 29% |
| Series C | 1 | 14% |
| Series D | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 3 | 43% |
| United States | 3 | 43% |
| Ireland | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Biobeat | Biobeat develops a wearable device for continuous, noninvasive, accurate, medical-grade monitoring of vital signs that include blood pressure, oxygen saturation, respiratory rate, heart rate, consciousness, cardiac output, stroke volume, body temperature, steps, and sweat. Its wearable device automatically uploads the recorded data to asmartphone-based application and to the cloud, where the application can monitor it remotely. Caretakers can intervene if needed, and users can receive alerts directly from the app. This provides caretakers with an important tool to assist in disease management and optimize clinical outcomes. The Biobeat system also facilitates remote monitoring of patients with a variety of medical issues. Ultimately, this solution allows patients to be treated in their homes. It can monitor stationary patients as well as those who perform outdoor activities. In 2018, Biobeat received FDA 510K clearance (K181006) for its monitoring system and partnered with DRIVe, a division of the Biomedical Advanced Research and Development Authority, to develop a wearable monitoring device that diagnoses the flu and infections before any symptoms appear. In August 2019, Biobeat received 510K FDA clearance for its patch and watch. | $50M | Series B | Dec 30, 2025 |  |
| ProVerum Medical | ProVerum Medical is a healthcare company that develops innovative treatments for benign prostatic hyperplasia (BPH). ProVerum develops the ProVee System, which is a minimally invasive implant that gently opens the blocked part of the urethra without cutting, heating, or removing tissue. | $80M | Series B | Aug 25, 2025 |  |
| Alentis Therapeutics | Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases. | $181.4M | Series D | Nov 12, 2024 |  |
| Asceneuron | Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression. | $100M | Series C | Jul 16, 2024 |  |
| Anjarium Biosciences | Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic diseases throughout a patient's lifetime. Combining deep domain expertise in synthetic and natural delivery systems, Anjarium is developing a novel class of bioinspired nanomedicine to address arange of genetic diseases, including those that necessitate very large gene delivery. Anjarium’s versatile platform systematically addresses key deficiencies of viral gene therapies in order to provide benefits to patients that have previously been out of reach. | $60.4M | Series A | Sep 15, 2021 |  |
| Spruce Biosciences | Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system. The company is driven by a mission to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have beenunderserved by scientific innovation. | $88M | Series B | Feb 20, 2020 |  |
| Attenua | Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics. They believe small molecule Blockbuster drugs that would benefit millions are still to be discovered.They have assembled a team of leading scientists and ex-Big Pharma advisorswith many years of drug development expertise. Their team has previous work experience at Merck, GSK, AstraZeneca, and Genentech. | $35M | Series A |  |  |

7 of 7 investments shown.

## Co-investors
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 4 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 3 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 2 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 2 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 1 deal together

## About OrbiMed

VC Fund · New York, United States

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investmentsseries of venture capital funds and a family of public equity investment funds.

5 contacts available at OrbiMed.

| Name | Title | Profile |
| --- | --- | --- |
| Dina Chaya | Partner | https://shizune.co/investors/profile/dina-chaya |
| Kevin Koch | Venture Partner | https://shizune.co/investors/profile/kevin-koch |
| Rishi Gupta | Private Equity Partner | https://shizune.co/investors/profile/rishi-gupta |
| Sunny Sharma | Senior Managing Director | https://shizune.co/investors/profile/sunny-sharma |
| Tadd S. Wessel | Managing Director | https://shizune.co/investors/profile/tadd-s-wessel |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Dina Chaya invest in?

Dina Chaya invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dina Chaya last invest?

The most recent investment recorded for Dina Chaya closed in Dec 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co